Did Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) Get A Major Breakthrough?
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), a bio-pharmaceutical company, has announced positive results of LX4211 in a Type 2 diabetes patients with renal impairment. LX4211, a drug candidate inhibits both sodium glucose transporters 1 (SGLT1) and 2 (SGLT12), successfully treated patients with type 2 diabetes, the company claimed.
In the study, LX4211 lowered post-prandial glucose in patients suffering from type 2 Diabetes and renal impairment from moderate to severe range. The key objective of the LX4211 is to reduce post-prandial glucose and high blood sugar levels post meals.
In a proof-of-concept study, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) said its LX4211 provided “clinically meaningful” significant reductions (p<0.05) in post-prandial glucose in diabetic patients who suffer from renal impairment from moderate to severe range (Stage 3 and 4 kidney disease). LX4211 also produced significant elevations in a hormone involved in control of glucose and appetite, GLP-1.
Renal impairment occurs in about 30% of patients with type 2 diabetes and comes with limited treatment options. LX4211, according to Lexicon, offers the potential for treating this 30% population with compromised kidney function.
“Our hypothesis was that LX4211 would improve glycemic control even in patients with the greatest degree of renal impairment due to its inhibition of SGLT1 in the GI tract,” said Pablo Lapuerta, M.D., Lexicon’s chief medical officer. “The post-prandial glucose reductions and GLP-1 elevations observed in this study population support the rationale for demonstrating effective HbA1c reduction in a larger, longer-term Phase 3 trial, and provide further support for the clinical differentiation of LX4211 as a first-in-class dual SGLT1 and SGLT2 inhibitor.”
In a Phase 2b study, LX4211 demonstrated a reduction in hemoglobin A1c (HbA1c) in patients diagnosed with type 2 diabetes. The drug treatment also produced significant reductions in body weight and blood pressure. In previous Phase 2 studies, the drug candidate was successful in improving glycemic control in patients with type 2 diabetes with normal renal function.
The company is planning to showcase the full results of the proof-of-concept study at scientific congresses next year.